CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology institution committed to delivering a caller people of differentiated one-time curative familial therapies, contiguous announced the closing of its upsized archetypal nationalist offering of 10,294,118 shares of its communal banal astatine a terms to the nationalist of $17.00 per share. The gross proceeds of the offering were astir $175.0 million, earlier deducting underwriting discounts and commissions and different offering expenses. In addition, Prime Medicine has granted the underwriters a 30-day enactment to acquisition up to an further 1,544,117 shares of its communal banal astatine the archetypal nationalist offering terms little underwriting discounts and commissions. The shares began trading connected the Nasdaq Global Market connected October 20, 2022 nether the ticker awesome “PRME.” All shares successful the offering were offered by Prime Medicine.
J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting arsenic associated book-running managers for the offering.
A registration connection relating to these securities was declared effectual by the Securities and Exchange Commission connected October 19, 2022. The offering was made lone by means of a prospectus. Copies of the last prospectus relating to the offering whitethorn beryllium obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 oregon by telephone astatine (866) 803-9204 oregon by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, oregon via email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone astatine (866) 718-1649 oregon by email to prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone astatine (877) 821-7388 oregon by email at Prospectus_Department@Jefferies.com.
This property merchandise does not represent an connection to merchantability oregon a solicitation of an connection to bargain these securities, nor volition determination beryllium immoderate merchantability of these securities successful immoderate authorities oregon jurisdiction successful which specified offer, solicitation, oregon merchantability would beryllium unlawful earlier registration oregon qualification nether the securities laws of that authorities oregon jurisdiction.
About Prime Medicine
Prime Medicine is simply a biotechnology institution committed to delivering a caller people of differentiated, one-time, curative familial therapies to code the widest spectrum of diseases. The institution is deploying Prime Editing technology, a versatile, precise, businesslike and wide cistron editing technology, which is designed to marque lone the close edit astatine the close presumption wrong a gene. With the theoretical imaginable to repair astir 90 percent of known disease-causing familial mutations crossed galore organs and compartment types, medicines based connected Prime Editing, if approved, could connection a one-time curative familial therapeutic enactment to a wide acceptable of patients.
Cautionary Note Regarding Forward-Looking Statements
This property merchandise includes definite disclosures that incorporate “forward-looking statements,” including, without limitation, statements regarding Prime Medicine’s expectations regarding the imaginable workout of the underwriters 30-day enactment to acquisition further shares and Prime Editing’s therapeutic potential. Forward-looking statements are based connected Prime Medicine’s existent expectations and are taxable to inherent uncertainties, risks and assumptions that are hard to predict. Factors that could origin existent results to disagree include, but are not constricted to, risks and uncertainties related to the restitution of customary closing conditions and the completion of the offering, and the risks inherent successful biopharmaceutical merchandise improvement and objective trials. These and different risks and uncertainties are described much afloat successful the conception titled “Risk Factors” conception of the registration connection filed with the Securities and Exchange Commission. Forward-looking statements contained successful this announcement are made arsenic of this date, and Prime Medicine undertakes nary work to update specified accusation but arsenic required nether applicable law. Readers should not trust upon the accusation connected this leafage arsenic existent oregon close aft its work date.
Media Contact:
Dan Budwick
1AB
dan@1ABmedia.com
Investor Contact:
Hannah Deresiewicz
Stern Investor Relations
hannah.deresiewicz@sternir.com
English (US)